Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of GR1501 injection in chronic moderate to severe plaque psoriasis
ChiCTR2100043223Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of xeligekimab in plaque psoriasis, sponsored by Peking University People's Hospital. Started Feb 2021; status: recruiting.
02
Drugs
xeligekimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2100043223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043223.